ArticleFrontiers in medicine2026
Combined PD-L1/CD8 immune phenotyping in breast cancer: exploratory associations across molecular subtypes and insights into possible exhaustion-related immune dysfunction.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Programmed death-ligand 1 (PD-L1) expression and CD8+ tumor-infiltrating lymphocyte (TIL) density are established biomarkers of tumor-immune interaction in breast cancer; however, the biological and prognostic significance of their combined assessment across molecular subtypes remains incompletely defined. This study aimed to characterize combined PD-L1/CD8 immune phenotypes, evaluate their clinicopathological associations, and explore their relationship with survival outcomes in a molecularly heterogeneous breast cancer cohort. Methods: This multicenter retrospective study included 137 patients with invasive breast carcinoma from two institutions. PD-L1 expression was evaluated separately in tumor cells (TCs) and tumor-infiltrating lymphocytes (TILs) by immunohistochemistry. CD8+ TIL density was also assessed immunohistochemically, and tumors were classified as CD8-high or CD8-low using a predefined threshold of ≥50%. Based on combined PD-L1 and CD8 status, cases were categorized into four immune phenotypes: Type I (PD-L1+/CD8-high), Type II (PD-L1+/CD8-low), Type III (PD-L1-/CD8-high), and Type IV (PD-L1-/CD8-low). Associations between immune phenotypes, clinicopathological characteristics, and survival outcomes were analyzed using appropriate statistical methods. Results: PD-L1 positivity was observed in 62 of 137 tumors (45.3%) and was significantly associated with higher histological grade ( Conclusions: Combined PD-L1/CD8 immune phenotyping identifies biologically distinct immune microenvironmental states in breast cancer beyond conventional molecular subtype classification. While PD-L1 positivity was associated with high histological grade and immune-cell infiltration, the PD-L1+/CD8-high phenotype demonstrated the least favorable survival profile in this predominantly hormone receptor-positive cohort on unadjusted analysis, an association that was attenuated to borderline significance after adjustment for baseline metastatic burden. These findings support the concept that concurrent PD-L1 expression and abundant CD8+ T-cell infiltration may not invariably reflect effective antitumor immunity and may instead be consistent with an exhausted or functionally impaired immune state. If validated in larger cohorts with direct assessment of T-cell exhaustion markers, combined PD-L1/CD8 phenotyping may provide clinically relevant insights for immune stratification and patient selection in immunotherapy-oriented approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.